Key Highlights
- Enterprise-Grade Solution: Ryght introduces an innovative platform designed to securely develop and deploy GenAI applications, enhancing scientific research, clinical operations, and commercialization for life science companies.
- Cost-Effective Innovation: Addressing the high costs and resource allocation of internal GenAI development, Ryght offers a scalable, secure, and adaptable AI solution that integrates into life science workflows.
- Strategic Partnership: Ryght collaborates with BEK Health to co-develop applications, enhancing patient matching in clinical trials and accelerating medical research.
Source: PR Newswire
Notable Quotes
- “Ryght is enterprise-grade, secure, and easy to deploy across life science companies of all sizes,” – Simon Arkell, CEO at Ryght
- “We are excited to join forces with Ryght and leverage their GenAI platform and expertise,” – Dave Levin, CEO at BEKHealth
SoH's Take
Ryght’s latest announcement marks a significant stride in the life science industry, bringing forward a robust GenAI platform designed with security, adaptability, and cost-effectiveness at its core. By enabling life science companies to incorporate GenAI into their operations, Ryght is not just offering a tool but an ecosystem of innovation, where secure data handling and workflow optimization are paramount. The strategic partnership with BEK Health further underscores the potential of collaborative innovation, promising to enhance the efficiency and scope of clinical research. As companies increasingly seek to leverage AI without the prohibitive costs and complexities of internal development, Ryght’s solution represents a compelling proposition, positioning itself as a catalyst for accelerated scientific discovery and operational excellence in the biopharma sector.
